Cargando…

Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin

BACKGROUND: Serum protein induced by vitamin K absence or antagonist-II (PIVKA-II) is a promising biomarker for hepatocellular carcinoma (HCC) surveillance. AIM: To identify the contributing factors related to the abnormal elevation of PIVKA-II level and assess their potential influence on the perfo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Xiang-Jun, Wen, Zhu-Mei, Huang, Xiao-Ming, Feng, Hui-Juan, Lin, Shan-Shan, Liu, Yan-Na, Li, Sheng-Cong, Zhang, Yu, Peng, Wen-Guang, Yang, Jia-Rui, Zheng, Zhe-Yu, Zhang, Lei, Zhang, Da-Wei, Lu, Feng-Min, Liu, Li-Juan, Pan, Wei-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Observational Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011960/ https://www.ncbi.nlm.nih.gov/pubmed/36925461 http://dx.doi.org/10.3748/wjg.v29.i8.1359

Ejemplares similares

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
por: Ji, Jun, et al.
Publicado: (2021)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

Associations between serum total bilirubin, obesity and type 2 diabetes
por: Wei, Yuan, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Facultative Endosymbiont Serratia symbiotica Inhibits the Apterization of Pea Aphid To Enhance Its Spread
por: Kang, Zhi-Wei, et al.
Publicado: (2022)

Gut phageome of the giant panda (Ailuropoda melanoleuca) reveals greater diversity than relative species
por: Lu, Juan, et al.
Publicado: (2023)

Change of tumor-infiltrating lymphocyte of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma
por: Wang, Wei, et al.
Publicado: (2022)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

Correlation Between Total Bilirubin, Total Bilirubin/Albumin Ratio with Disease Activity in Patients with Rheumatoid Arthritis
por: Zhang, Hui, et al.
Publicado: (2023)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Safety of elective hepatectomy performed on weekend for patients with hepatocellular carcinoma
por: Dai, Junlong, et al.
Publicado: (2022)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

Selective lateral lymph node dissection after neoadjuvant chemoradiotherapy in rectal cancer
por: Chen, Jia-Nan, et al.
Publicado: (2020)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma
por: Villalba-López, Francisco, et al.
Publicado: (2023)

Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes
por: Liu, Zhi-Jie, et al.
Publicado: (2023)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma
por: Shi, Bao-Min, et al.
Publicado: (2017)

Development and validation of a risk assessment model for prediabetes in China national diabetes survey
por: Yu, Li-Ping, et al.
Publicado: (2022)

Comparison of pathological findings between patients with relapsed and non-relapsed immunoglobin G4-related disease
por: Lu, Hui, et al.
Publicado: (2022)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study
por: Wu, Feng-Ping, et al.
Publicado: (2020)

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China
por: Yang, Ying, et al.
Publicado: (2019)

Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis
por: Sheng, Lang-Qing, et al.
Publicado: (2020)

Modified EASL-CLIF criteria that is easier to use and perform better to prognosticate acute-on-chronic liver failure
por: Thuluvath, Paul J, et al.
Publicado: (2022)

Emergence and Comparative Genomics Analysis of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Carrying mcr-1 in Fennec Fox Imported from Sudan to China
por: Feng, Chunyan, et al.
Publicado: (2019)

Multi-parameter ultrasound based on the logistic regression model in the differential diagnosis of hepatocellular adenoma and focal nodular hyperplasia
por: Wu, Meng, et al.
Publicado: (2019)

The gender-specific bidirectional relations between chronic diseases and total bilirubin/urea in the elderly population: A 3-year longitudinal study
por: Wu, Na, et al.
Publicado: (2022)

Deep learning-based radiomics based on contrast-enhanced ultrasound predicts early recurrence and survival outcome in hepatocellular carcinoma
por: Huang, Zhe, et al.
Publicado: (2022)

Feasibility of terahertz imaging for discrimination of human hepatocellular carcinoma
por: Duan, Feng, et al.
Publicado: (2019)

The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
por: Kang, Keunhee, et al.
Publicado: (2015)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3n0mniiaa8iad2ocbrrfbhlnf